Abstracts tagged "Patient reported outcomes"

Abstract Number: 1563 • ACR Convergence 2024
Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma
Gayane Matusov¹, Jon Giles² and Francesco Boin³, ¹Scripps Clinic, San Diego, CA, ²Cedars Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Case-control studies have shown that systemic sclerosis (SSc) patients exhibit higher prevalence of osteoporosis (OP) compared to subjects in the general population. The pathophysiology…
Abstract Number: 2154 • ACR Convergence 2024
“I Have Taken Five Different Kinds of Tablets and Injections, and I Still Have Foot Pain”: An International Outcome Measures in Rheumatology (OMERACT) Qualitative Study Exploring Patient Perspectives of Foot and Ankle Disorders
Lara Chapman¹, Caroline Flurey², Anthony C. Redmond¹, Pam Richards³, Eiman Soliman⁴, Abdelhfeez Moshrif⁵, Lucy Malone⁶, Christopher Joyce⁷, Marian Hannan⁸, Philip S. Helliwell⁹, Catherine Hofstetter¹⁰, Hylton Menz¹¹, Beverley Shea¹² and Heidi Siddle¹, ¹University of Leeds, Leeds, United Kingdom, ²University of the West of England, Bristol, Bristol, United Kingdom, ³OMERACT, Bristol, United Kingdom, ⁴Alexandria Faculty of Medicine, Alexandria, Egypt, ⁵Al-azhar university, Assiut, Egypt, ⁶Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom, ⁷Homerton Healthcare NHS Foundation Trust, London, United Kingdom, ⁸Marcus Institute for Aging Research, Hebrew SeniorLife, Milton, MA, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ¹⁰OMERACT, Toronto, Canada, ¹¹La Trobe University, Fairfield, Victoria, Australia, ¹²Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: The foot and ankle are frequently affected in rheumatic and musculoskeletal diseases (RMDs), yet there is a lack of high-quality evidence to determine the…
Abstract Number: 2336 • ACR Convergence 2024
Patients with Psoriasis with a Positive Psoriasis Epidemiology Screening Tool (PEST): Similarities and Differences Compared to PsA and Patients with Psoriasis and a Negative PEST
Alexis Ogdie¹, William Song², Joel Gelfand², Sarah Lonowski³, Rebecca Schumacher⁴ and Kaleb Michaud³, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Forward Databank, Witchita, KS
Background/Purpose: Identifying patients at risk for developing psoriatic arthritis (PsA) may allow for accelerated diagnosis and treatment and improve long term outcomes for these patients.…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…
Abstract Number: 0561 • ACR Convergence 2024
Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort
Annie Brink¹, Elisabeth Mogard², Elisabet Lindqvist², Jonas Sagard², Johan Karlsson Wallman¹ and Tor Olofsson², ¹Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden
Background/Purpose: A growing arsenal of biologic/targeted synthetic DMARDs often makes inflammation control an attainable target in axial spondyloarthritis (axSpA). Yet, many patients keep suffering from…
Abstract Number: 0720 • ACR Convergence 2024
Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care
javier Merayo Chalico¹, Ana Sarahí Mulia-Soto², María Espinosa-León³, Victor Pimentel-Quiroz⁴, Ana Barrera-Vargas³ and Andrea Hinojosa-Azaola³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁴Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru
Background/Purpose: Systemic vasculitides comprise a group of inflammatory diseases involving multiple organ systems, significantly affecting various aspects of a patient's life, including their sexuality. Sexual…
Abstract Number: 1242 • ACR Convergence 2024
Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms
Joseph F. Merola¹, Victoria Werth², Jiyoon C. Choi³, Brandon Becker³, Teresa Edwards⁴, Coburn Hobar⁵, Samantha Pomponi⁵ and Vibeke Strand⁶, ¹UT Southwestern Medical Center, Dallas, TX, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³Bristol Myers Squibb, Princeton, ⁴RTI International, Research Triangle Park, NC, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that disproportionately impacts women of childbearing age. Although the incidence varies widely based on ethnic…
Abstract Number: 1332 • ACR Convergence 2024
Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Amber Brown Keebler¹, Yunju Im², Sofia Pedro³, Ted Mikuls¹, Edward Peters¹ and Kaleb Michaud¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Often not evaluated in clinical visits, financial distress associated with medical costs, also known as financial toxicity, has emerged as an important factor affecting…
Abstract Number: 1576 • ACR Convergence 2024
New Patient-Reported Outcome Measures for Early Systemic Sclerosis Using the FDA Guidance on Patient Reported Outcome Measures
Dinesh Khanna¹, George greene², Chelsea Perschon², Alain Lescoat³, Emilie Jaeger², Susan murphy¹ and David Cella⁴, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago, ³CHU Rennes - University Rennes 1, Rennes, France, ⁴Northwestern University, Chicago, IL
Background/Purpose: Systemic sclerosis (SSc) is associated with a wide range of symptoms and significant impairments in function and quality of life. The goal of the…
Abstract Number: 2155 • ACR Convergence 2024
Direct Comparison of Sleep Quality and Risk Factors for Poor Sleep Across Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis
Dagna Polak¹, Mateusz Wilk², Piotr Kuszmiersz¹, Glenn Haugeberg³, Mariusz Korkosz⁴ and Zofia Guła⁴, ¹University Hospital in Cracow, Kraków, Poland, ²Univesity Hospital in Cracow, Kraków, Poland, ³Sørlandet Hospital, Kristiansand, Kristiansand, Norway, ⁴Department of Rheumatology and Immunology, Jagiellonian University Medical College, Kraków, Poland

Background/Purpose: Sleep disorders are common among patients with inflammatory arthritis (IA) and have probably bilateral influence on disease activity and quality of life. Pathomechanism of…
Abstract Number: 2365 • ACR Convergence 2024
Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry
Philip Mease¹, Xiaolan Ye², Christopher Saffore³, Thomas Iyile⁴, Priscila Magalhaes Reis Nakasato⁵, Taylor Blachley⁶, Paul R. Lakin⁶, Nicole Middaugh⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., hyattsville, MD, ⁵AbbVie Inc., Randolph, NJ, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Treatment for psoriatic arthritis (PsA) often involves biologic and targeted synthetic DMARDs (b/tsDMARDs). Existing research suggests that starting treatment with b/tsDMARDs early may lead…
Abstract Number: 0264 • ACR Convergence 2024
Clinical Value of Metagenomic Next-generation Sequencing in Patients with Connective Tissue Disease Co-infections: A Single-center Study from Southern Hospital in China
Yuan-Yuan Xiao¹, Ai-Ling Lu¹, Han-You Mo², Zhen-Dong He², Jia-Le Wen² and Xuan Yin¹, ¹Guilin Medical University, Guilin, China (People's Republic), ²The First Affiliated Hospital of Guangxi Medical University, Nanning, China (People's Republic)
Background/Purpose: Few studies have been reported on the use of metagenomic next-generation sequencing (mNGS) in patients with connective tissue disease (CTD) co-infections, and more relatively large-scale data…
Abstract Number: 0571 • ACR Convergence 2024
Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study
Sabrina Hamroun¹, Laure Gossec², Serge Perrot³, Maxime Dougados⁴ and Anna Molto⁵, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Sorbonne Université, Paris, France, ³Paris Dauphine University, Paris, France, ⁴Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁵Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: There are several tools for assessing disease activity in spondyloarthritis (SpA). The literature reveals gender differences, with unfavorable Patient Reported Outcomes in women compared…
Abstract Number: 0730 • ACR Convergence 2024
Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes
Michele Moretti¹, Elena Elefante², Francesco Ferro³, Ludovica Pisapia⁴, Federica Di Cianni⁵, Nazzareno Italiano⁶, ROSARIA TALARICO⁵, Chiara Baldini⁷ and Marta Mosca⁷, ¹University of Pisa, Pisa, Pisa, Italy, ²Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶University of Pisa, Rovigo, Italy, ⁷University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: ANCA-associated vasculitides (AAVs) are characterized by severe and multisystemic manifestations that greatly affect patients' quality of life (QoL). The purpose of the study was…
Abstract Number: 1243 • ACR Convergence 2024
A Patient-Focused Program for Using Steroids Wisely
John Stone¹, Michelle Petri², Jeffrey Gelfand³, Camille Kotton⁴, Jane McDowell⁵, George Papaliodis⁶, meredith Marinaro⁷, Matt Wilkinson⁸, Walter Lentfert⁹ and Martha Stone¹⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Harvard Medical School, Boston, MA, ⁵Queens University Belfast, Belfast, Ireland, ⁶Massachusetts General Hospital, Boston, MA, ⁷Novartis, Hartford, CT, ⁸UpThereEverywhere, London, United Kingdom, ⁹UpThereEverywhere, Wilmington, NC, ¹⁰Steritas, LLC, CONCORD, MA
Background/Purpose: Patients have no comprehensive, curated resource on steroid use to facilitate effective collaboration in their own care. Consequently, truly shared decision making around steroid…

« Previous Page
1
…
3
4
5
6
7
…
43
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].